Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Common Equity (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Common Equity for 6 consecutive years, with $123.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 48.91% to $123.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123.1 million through Dec 2025, down 48.91% year-over-year, with the annual reading at $123.1 million for FY2025, 48.91% down from the prior year.
  • Common Equity for Q4 2025 was $123.1 million at TScan Therapeutics, down from $144.0 million in the prior quarter.
  • The five-year high for Common Equity was $255.2 million in Q2 2024, with the low at -$60.0 million in Q2 2021.
  • Average Common Equity over 5 years is $140.5 million, with a median of $148.3 million recorded in 2022.
  • Peak annual rise in Common Equity hit 599.57% in 2021, while the deepest fall reached 115.9% in 2021.
  • Over 5 years, Common Equity stood at $160.8 million in 2021, then plummeted by 38.15% to $99.4 million in 2022, then soared by 51.73% to $150.9 million in 2023, then surged by 59.72% to $241.0 million in 2024, then crashed by 48.91% to $123.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $123.1 million, $144.0 million, and $176.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.